Sector
PharmaceuticalsOpen
₹910.1Prev. Close
₹905.6Turnover(Lac.)
₹70.62Day's High
₹949.85Day's Low
₹897.552 Week's High
₹1,753.9552 Week's Low
₹762.6Book Value
₹687.37Face Value
₹10Mkt Cap (₹ Cr.)
537.88P/E
31.56EPS
29.81Divi. Yield
0.5313 May 2024
12:00 AM
Dividend
Dividend Amount: 11.5
Record Date: 02 Aug, 2024
6 May 2025
12:00 AM
Board Meeting
Agenda : Audited Result
13 May 2024
12:00 AM
AGM
Announcement Date: 13 May, 2024
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 5.71 | 5.71 | 5.71 | 5.71 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 386.78 | 377.27 | 305.87 | 273.76 |
Net Worth | 392.49 | 382.98 | 311.58 | 279.47 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Revenue | 320.79 | 287.45 | 295.32 | 322.6 |
yoy growth (%) | 11.59 | -2.66 | -8.45 | 0.25 |
Raw materials | -105.39 | -90.93 | -85.04 | -94.68 |
As % of sales | 32.85 | 31.63 | 28.79 | 29.35 |
Employee costs | -90.33 | -84.53 | -83.17 | -81.6 |
| Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Profit before tax | 28.95 | 21.54 | 27.23 | 22.21 |
Depreciation | -7.67 | -8.23 | -7.51 | -8.99 |
Tax paid | -9.78 | -8.06 | -10.17 | -15.02 |
Working capital | -38.2 | -2.63 | -1.62 | 8.15 |
Other operating items |
| Y/e 31 Mar | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 11.59 | -2.66 | -8.45 | 0.25 |
Op profit growth | 39.53 | -22.03 | -10.27 | -15.11 |
EBIT growth | 32.79 | -19.91 | 16.44 | 4.6 |
Net profit growth | 94.78 | -38.32 | -66.75 | 250.32 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,672 | 93.86 | 4,01,288.77 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,835 | 82.12 | 1,81,397.34 | 667 | 0.44 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,485 | 24.92 | 1,19,948.65 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,314.2 | 59.26 | 1,12,127.01 | 474 | 0.18 | 2,385 | 224.34 |
Mankind Pharma Ltd MANKIND | 2,578.3 | 56.47 | 1,06,401.47 | 382.46 | 0 | 2,126.59 | 354.71 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Chairman
A K Kothari
Non Executive Director
Prabhawati Devi Kothari
Independent Director
Monjori Mitra
Non Executive Director
Anand Vardhan Kothari
Managing Director & CEO
U. M. Kunte
Independent Director
Anurag Singhi
Independent Director
Shourya Sengupta
Independent Director
Naresh Pachisia
D Block 3rd Flr Gillander Hous,
Netaji Subhas Road,
West Bengal - 700001
Tel: 91-33-22302330/2262 8436/8456/
Website: http://www.albertdavidindia.com
Email: albertdavid@adlindia.in; abchakrabartty@adlindia.i
23 RN Mukherjee Road,
5th Floor,
Kolkata-700001
Tel: 91-33-22435029/22482
Website: www.mdpl.in
Email: info@mdpl.in
Summary
Albert David Limited (ADL), a Unit of Kothari Group, was incorporated in 1938 at Calcutta. The Company belongs to a renowned industrial house of Kolkata, the Kothari Group. The Companys principal busi...
Read More
Reports by Albert David Ltd
What is the Albert David Ltd share price today?
What is the Market Cap of Albert David Ltd?
What is the PE and PB ratio of Albert David Ltd?
What is the 52 Week High and Low of Albert David Ltd?
What is the CAGR of Albert David Ltd?
What is the shareholding pattern of Albert David Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.